Agios Pharm (AGIO) financial statements
Agios Pharm reported revenue of $54M in fiscal 2025, down 2.8% a year over 9 years.
Net income was -$413M and the operating margin -873.9%, against -287.6% in 2016.
Free cash flow was -$377M.
The diluted share count rose 48% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Agios Pharm's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70M | $43M | $94M | $118M | $0 | $0 | $14M | $27M | $36M | $54M |
| Cost of revenue | $0 | $0 | $1M | $1M | $0 | $0 | $2M | $3M | $4M | $6M |
| Gross profit | $70M | $43M | $93M | $117M | $0 | $0 | $13M | $24M | $32M | $48M |
| Research and development | $220M | $293M | $341M | $214M | $221M | $257M | $280M | $296M | $301M | $340M |
| Selling, general and admin | $51M | $71M | $114M | $102M | $115M | $121M | $122M | $120M | $157M | $180M |
| Operating income | -$201M | -$321M | -$362M | -$316M | -$336M | -$378M | -$389M | -$391M | -$426M | -$472M |
| Pre-tax income | -$198M | -$315M | -$346M | -$301M | -$329M | -$357M | -$232M | -$352M | $718M | -$414M |
| Income tax | $0 | $0 | $0 | $0 | — | — | $0 | $0 | $44M | -$1M |
| Net income | -$198M | -$315M | -$346M | -$411M | -$327M | $1.6B | -$232M | -$352M | $674M | -$413M |
| EPS (diluted) | -$5.07 | -$6.75 | -$6.03 | -$6.86 | -$4.74 | $26.55 | -$4.23 | -$6.33 | $11.64 | -$7.12 |
| Diluted shares | 39M | 47M | 57M | 60M | 69M | 60M | 55M | 56M | 58M | 58M |
| Gross margin | 100.0% | 100.0% | 98.5% | 98.9% | — | — | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating margin | -287.6% | -745.8% | -384.0% | -268.2% | — | — | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Net margin | -284.0% | -731.6% | -366.6% | -349.0% | — | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
Balance sheet
Fiscal years, from Agios Pharm's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $574M | $568M | $805M | $718M | $670M | $1.3B | $1.1B | $806M | $1.5B | $1.2B |
| Inventory | — | $0 | $869,000 | $7M | $15M | $0 | $8M | $19M | $28M | $33M |
| Total current assets | $560M | $445M | $614M | $612M | $637M | $1.1B | $833M | $834M | $966M | $942M |
| Property, plant and equipment | $25M | $24M | $24M | $31M | $31M | $29M | $23M | $15M | $12M | $11M |
| Total assets | $619M | $614M | $858M | $891M | $853M | $1.4B | $1.2B | $937M | $1.7B | $1.3B |
| Total current liabilities | $88M | $95M | $94M | $93M | $94M | $60M | $63M | $68M | $81M | $82M |
| Total liabilities | $261M | $239M | $171M | $250M | $453M | $146M | $138M | $126M | $122M | $104M |
| Shareholders' equity | $359M | $376M | $688M | $641M | $400M | $1.3B | $1.1B | $811M | $1.5B | $1.2B |
| Net debt | -$161M | -$103M | -$71M | -$81M | -$127M | -$203M | -$139M | -$88M | -$76M | -$89M |
Cash flow
Fiscal years, from Agios Pharm's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $39M | -$285M | -$304M | -$371M | -$291M | -$407M | -$309M | -$296M | -$390M | -$373M |
| Capital spending | $10M | $5M | $7M | $12M | $14M | $6M | $5M | $999,000 | $2M | $4M |
| Free cash flow | $29M | -$290M | -$311M | -$383M | -$305M | -$413M | -$314M | -$297M | -$392M | -$377M |
| Stock-based compensation | $42M | $48M | $73M | $58M | $62M | $54M | $49M | $45M | $43M | $53M |
| Free cash flow margin | 41.0% | -673.9% | -329.9% | -324.5% | — | — | -2207.6% | -1107.5% | -1072.7% | -698.3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AGIO.
Open AGIO in InvestinglyQuestions
What was Agios Pharm's revenue in 2025?
$54M in fiscal 2025, from its 10-K filing.
How much free cash flow does Agios Pharm generate?
-$377M in fiscal 2025 (operating cash flow minus capital spending).
From Agios Pharm's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.